Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib versus ruxolitinib in myelofibrosis
2013-002707-33Phase 3Completed
- Sponsor
- Sierra Oncology
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more comparing Momelotinib arm with Ruxolitinib arm (2 arms). Primary endpoint: Splenic response rate at Week 24. Started Jan 2014; status: completed.
02
Drugs
mivavotinibruxolitinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2013-002707-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002707-33.